Tongxinluo inhibits oxidized low-density lipoprotein-induced maturation of human dendritic cells via activating peroxisome proliferator-activated receptor gamma pathway

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 2, 2010, Pages 177-183

  Su, Wei ^a,b   Sun, Aijun ^a   Xu, Danling ^a   Zhang, Hongqi ^a   Yang, Lin ^a   Yuan, Lingyan ^a   Jia, Jianguo ^a   Zou, Yunzeng ^a   Wu, Yiling ^c   Wang, Keqiang ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c Western Medical Research Academy of Hebei Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CD40 ANTIGEN; CD86 ANTIGEN; CHINESE DRUG; CIGLITAZONE; HLA DR ANTIGEN; INTERLEUKIN 12; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMALL INTERFERING RNA; T6 ANTIGEN; TONGXINLUO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL FUNCTION; CELL MATURATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA INTERFERENCE;

ANTIGENS, CD1; ANTIGENS, CD40; ANTIGENS, CD86; CELLS, CULTURED; DENDRITIC CELLS; DRUGS, CHINESE HERBAL; ENDOCYTOSIS; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-12; LIPOPROTEINS, LDL; PPAR GAMMA; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955981438     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181e5f0f8     Document Type: Article

References (31)

1. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol. 2010;134:25-32.
2. Bobryshev YV Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J. 2005;26:1700-1704.
3. Bobryshev YV Lord RS. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intiM.A. Contacting interactions of vascular dendritic cells in athero-resistant and athero-prone areas of the normal aorta. Arch Histol Cytol. 1995;58:307-322.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
5. Xu Guicheng, Gao Ronglin, Liu Junling. Double blind control observation of TongXinLuo capsule on treatment of patients with angina pectoris caused by coronary heart disease. Chin New Drugs J. 2000;9:109-111.
6. You Shi-jie, Yang Yue-jin, Chen Ke-ji. The protective effects of TongXinLuo on myocardium and microvasculature after reperfusion in acute myocardal infarction. Zhonghua Xin Xue Guan Bing Za Zhi. 2005; 33:433-437.
7. Zhang L, Liu Y, Lu XT, et al. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy. Am J Physiol Heart Circ Physiol. 2009;297:H2004-H2014.
8. Li Zhen, Yang Yuejin, Qin Xue-en, et al. Effects of Tongxinluo and simvastatin on the stabilization of vulnerable atherosclerotic plaques of aorta in aortic atherosclerosis and molecular mechanism thereof: a comparative study with rabbits. Zhonghua Yi Xue Za Zhi. 2006;86: 3146-3150.
9. Luo Y, Liang C, Xu C, et al. Ciglitazone inhibits oxidized-low density lipoprotein induced immune maturation of dendritic cells. J Cardiovasc Pharmacol. 2004;44:381-385.
10. Bobryshev YV. Can dendritic cells be exploited for therapeutic intervention in atherosclerosis? Atherosclerosis. 2001;154:511-512.
11. Bobryshev YV Dendritic cells and their involvement in atherosclerosis. Curr Opin Lipidol. 2000;11:511-517.
12. Bobryshev YV, Lord RS. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res. 1995;29:689-696.
13. Bobryshev YV, Watanabe T. Subset of vascular dendritic cells transforming into foam cells in human atherosclerotic lesions. Cardiovasc Pathol. 1997;11:321-331.
14. Bobryshev YV, Lord RS. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res. 1998;37:799-810.
15. Zhang L, Wu Y, Jia Z, et al. Protective effects of acompound herbal extract (TongXinLuo) on free fatty acid induced endothelial injury: implications of antioxidant system. BMC Complement Altern Med. 2008; 14:38-48.
16. Li Z, Yang YJ, Qin XW, et al. Effects oftongxinluo and simvastatin on the stabilization of vulnerable atherosclerotic plaques of aorta in aortic atherosclerosis and molecular mechanism thereof: a comparative study with rabbits. Zhonghua Yi Xue Za Zhi. 2006;86:3146-3150.
17. Liu JX, Shang XH, Wang G. Effect oftongxinluo capsule on experimental myocardial ischemia, arrhythmia and hyperlipidemia. Zhongguo ZhongXi Yi Jie He Za Zhi. 1997;17:425-428.
18. Wu YL, You JH, Yuan GQ, et al. The effects of tongxinluo supermicro powder on nuclear factor-kappaB, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression in aorta of rabbits fed with high-lipid diet. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35: 271-274.
19. Schuurhuis DH, Laban S, Toes RE. Immature dendritic cells acquire CD8 (+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med. 2000;192: 145-150.
20. Gimmi CD, Freeman GJ, Gribben JG, et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA. 1993;90:6586-6590.
21. Pasare C, Medzhitov R. Toll-dependent control mechanisms ofCD4 T cell activation. Immunity. 2004;21:733-741.
22. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation. Impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1:311-316.
23. Wen Qiang Chena, Lin Zhongb, Lei Zhanga, et al. Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model. J Ethnopharmacol. 2009;124:103-110.
24. Atilla Yilmaz a, Christine Reiss, Omeima Tantawi, et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis. 2004;172:85-93.
25. Yilmaz A, Reiss C, Weng A. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006;79:529-538.
26. Bu PL, Zhao XQ, Wang LL, et al. Tong-xin-luo capsule inhibits left ventricular remodeling in spontaneously hypertensive rats by enhancing PPAR-gamma expression and suppressing NF-kappaB activity. Chin Med J (Engl). 2008;121:147-154.
27. Shang W, Yang Y, Jiang B, et al. Ginsenoside Rb1 promotes adipogenesis in 3T3-L1cells by enhancing PPAR gamma2 and C/CEPalpha gene expression. Life Sci. 2007;80:618-625.
28. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol. 2000; 60:1245-1250.
29. Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/ macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93: 241-252.
30. Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamM.A. Cell. 1998;93:229-240.
31. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.